Biosynth Bolsters Capabilities in Conjugate Vaccines and Bioconjugate Drugs Through Celares Acquisition
Customized Bioconjugation Solutions for Pharma and IVD Industries
Biosynth, a pivotal supplier of vital raw materials to the life science sector, is thrilled to announce its acquisition of celares, a renowned leader in the realm of conjugate vaccines and bioconjugate drugs. Additionally, celares specializes in activated PEGs and polymer-based drug delivery excipients.
This strategic acquisition announced on 11th July 2023, bolsters Biosynth’s presence within the rapidly expanding market for conjugate vaccines and bioconjugate drugs. With an enriched portfolio of capabilities, Biosynth is now poised to provide an array of bioconjugation services to its established pharma and diagnostics customer base.
Commenting, Dr. Urs Spitz, CEO and President of Biosynth, said:
“celares is an established leader in bioconjugation and we are extremely excited to be acquiring such a great team of specialists. celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery. Together, we can support customers from development to commercialisation. Celares is a perfect fit for Biosynth – where chemistry meets biology.”
Dr. Ralf Kraehmer, Managing Director of celares shared his enthusiasm, saying:
“We are thrilled to have joined the Biosynth group. As established leaders in bioconjugation, celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward-looking technologies. Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development. We see great similarities in Biosynth with their customer led strategy and passion for the life science industry”
For more information about Biosynth’s comprehensive contributions to the life science industry, please visit www.biosynth.com.
About Biosynth
Biosynth stands as a vital supplier of critical materials, ensuring the integrity of life science supply chains through its global research, manufacturing, and distribution facilities. Serving the pharmaceutical and diagnostic sectors, Biosynth operates at the crossroads of Chemistry and Biology, where Products meet Services and Innovation meets Quality. With an unparalleled research product portfolio featuring over a million products, and a spectrum of end-to-end manufacturing services, Biosynth excels in Complex Chemicals, Peptides, and Key Biologics, establishing itself as a trusted and comprehensive partner. Headquartered in Staad, Switzerland, Biosynth’s ownership includes entities such as KKR, Ampersand Capital Partners, and management.
About celares
celares GmbH is dedicated to the development and manufacturing of polymer-based drug delivery excipients and bioconjugate drugs. Established in 2003 and headquartered in Berlin, Germany, celares is a trailblazer in the field of bioconjugation and half-life extension through chemical modification, as well as the synthesis of specialty polymers for drug delivery. celares offers high-quality customized services, including feasibility studies, up-scaling and process development, along with the development and validation of required analytical methods. Additionally, celares provides GMP production of bioconjugates and functionalized polymers used as excipients in drug formulation.
